Pharmacotherapy Publishing Inc
View my basket
Atypon Link logo

You have no access to this article

Pharmacokinetics of Meropenem 0.5 and 2 g Every 8 Hours as a 3-Hour Infusion


Author(s): Prachi K. Dandekar | Dana Maglio | Christina A. Sutherland | Charles H. Nightingale | David P. Nicolau
doi: 10.1592/phco.23.8.988.32878
Prev | Table of contents | Next
 
View PDF article (108 K) View references
Email this link
 What is RSS?
Trouble viewing articles as PDF?
 
  Pharmacotherapy
 
Print ISSN: 0277-0008
Volume: 23 | Issue: 8
Cover date: August 2003
Page(s): 988-991
 
 
  Keywords
 
meropenem, pharmacokinetics
 
  Abstract

Study Objective. To assess the pharmacokinetics of meropenem administered as a 3-hour infusion.

Design. Randomized, crossover, open-label study.

Setting. Clinical research center.

Subjects. Six healthy adult male volunteers.

Intervention. Each subject received meropenem 0.5 or 2 g every 8 hours as a 3-hour infusion for three doses and then crossed over to the other dosage regimen.

Measurement and Main Results. Pharmacokinetic parameters of both regimens were compared, and no significant differences between 0.5- and 2-g doses for the dose-independent parameters (half-life, clearance, and volume of distribution at steady state) were observed. The regimens displayed dose proportionality and were consistent with that of a traditional 0.5-hour infusion. The 3-hour infusion optimized the pharmacodynamic profile of meropenem and worked within the constraints of stability at room temperature stability.

Conclusion. Prolonging the percentage of time above the minimum inhibitory concentration is a feasible option with meropenem; however, further studies are needed to quantify how this increase translates to efficacy.

 
  Author(s) affiliations
 
1. Center for Anti-Infective Research and Development, Hartford Hospital, Hartford, Connecticut.
2. Center for Anti-Infective Research and Development, Hartford Hospital, Hartford, Connecticut.
3. Center for Anti-Infective Research and Development, Hartford Hospital, Hartford, Connecticut.
4. Office for Research, Hartford Hospital, Hartford, Connecticut.
5. Center for Anti-Infective Research and Development, and the Division of Infectious Diseases, Hartford Hospital, Hartford, Connecticut.
Address reprint requests to David P. Nicolau, Pharm.D., FCCP, Center for Anti-Infective Research and Development, Hartford Hospital, 80 Seymour Street, Hartford, CT 06102; e-mail: dnicola@harthosp.org.
 
  This article has been cited by:
1.
 
Exploratory assessment of dose proportionality: review of current approaches and proposal for a practical criterion.
Jürgen Hummel, Sue McKendrick, Charlie Brindley, Raymond French.
Pharmaceutical Statistics |  8 |  1 |  38-49
CrossRef
2.
 
New developments in carbapenems.
J. N. Kattan, M. V. Villegas, J. P. Quinn.
Clinical Microbiology and Infection |  14 |  12 |  1102-1111
CrossRef
3.
 
The relationship between the daily dosage of the carbapenem meropenem (MEPM) and MEPM-resistant Pseudomonas aeruginosa.
Shin-ichi Harashima, Hiroko Kondo, Atsuko Nabeshima, Masako Shimoda, Kouzaburo Yamaji, Takahiko Horiuchi, Nobuyuki Shimono, Hideyuki Ikematsu.
Journal of Infection and Chemotherapy |  14 |  3 |  219-222
CrossRef
4.
 
Pharmacodynamics of antimicrobials: treatment optimisation.
Effie L Gillespie, Joseph L Kuti, David P Nicolau.
Expert Opinion on Drug Metabolism & Toxicology |  1 |  3 |  351-361
CrossRef
5.
 
Clinical Implications of Pharmacokinetics and Pharmacodynamics of Fluoroquinolones.
Brian Wispelwey.
Clinical Infectious Diseases |  41 |  s2 |  S127
CrossRef
6.
 
Meropenem Administered as a Prolonged Infusion to Treat Serious Gram-Negative Central Nervous System Infections.
Blair Capitano, , David P. Nicolau, , Brian A. Potoski, , Karin E. Byers, , Michael Horowitz, , Raman Venkataramanan, , David L. Paterson, .
Pharmacotherapy |  24 |  6 |  803-807
View Header/Abstract | View References | View PDF article (112 KB)